Clinical trial
Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation
NCT00402532 · Hannover Medical School, Other · Completed
Key facts
| NCT number | NCT00402532 |
|---|---|
| Title | Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation |
| Official title | Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation |
| Lead sponsor | Hannover Medical School, Other |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Transplantation |
| Intervention type | Drug |
| Interventions | Everolimus, Mycophenolatmofetil |
| Enrollment | 190 |
| Start date | Mar 1, 2005 |
| Primary completion | Nov 1, 2011 |
| Completion | Dec 1, 2011 |
| First posted | Nov 22, 2006 |
| Last update posted | Dec 8, 2011 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: